OmniAb Announces Global Collaboration and License Agreement with Eli Lilly For New Ion Channel Program; OmniAb To Receive An Upfront Payment and Is Eligible To Receive Up to $370M In R&D and Commercial Milestone Payments
The therapeutic target and modality are undisclosed.
OmniAb partnered with a big pharmaceutical company (Eli Lilly) to work on a new medicine together, and OmniAb will get paid money upfront plus more if the project hits important goals. This shows that larger companies believe OmniAb's science is valuable, which is a positive sign for the smaller company's future.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.